Acura Pharmaceuticals Company Profile (NASDAQ:ACUR)

About Acura Pharmaceuticals (NASDAQ:ACUR)

Acura Pharmaceuticals logoAcura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:ACUR
  • CUSIP: 00509L70
  • Web:
  • Market Cap: $8.58 million
  • Outstanding Shares: 20,795,000
Average Prices:
  • 50 Day Moving Avg: $0.45
  • 200 Day Moving Avg: $0.50
  • 52 Week Range: $0.40 - $1.40
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 1.12
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $6.79 million
  • Price / Sales: 1.26
  • Book Value: ($0.03) per share
  • Price / Book: -15.29
  • EBITDA: ($1,420,000.00)
  • Net Margins: -2,335.87%
  • Return on Equity: -1,237.56%
  • Return on Assets: -114.20%
  • Debt-to-Equity Ratio: -7.29%
  • Current Ratio: 1.25%
  • Quick Ratio: 1.15%
  • Average Volume: 11,534 shs.
  • Beta: 2.12
  • Short Ratio: 0.73

Frequently Asked Questions for Acura Pharmaceuticals (NASDAQ:ACUR)

What is Acura Pharmaceuticals' stock symbol?

Acura Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACUR."

How were Acura Pharmaceuticals' earnings last quarter?

Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) posted its earnings results on Monday, August, 14th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.07. The firm earned $0.09 million during the quarter. Acura Pharmaceuticals had a negative net margin of 2,335.87% and a negative return on equity of 1,237.56%. View Acura Pharmaceuticals' Earnings History.

Where is Acura Pharmaceuticals' stock going? Where will Acura Pharmaceuticals' stock price be in 2017?

0 equities research analysts have issued twelve-month target prices for Acura Pharmaceuticals' shares. Their forecasts range from $10,000,000.00 to $0.00. On average, they anticipate Acura Pharmaceuticals' share price to reach $0.00 in the next twelve months. View Analyst Ratings for Acura Pharmaceuticals.

Who are some of Acura Pharmaceuticals' key competitors?

Who are Acura Pharmaceuticals' key executives?

Acura Pharmaceuticals' management team includes the folowing people:

  • Robert B. Jones, President, Chief Executive Officer, Director
  • Peter A. Clemens, Chief Financial Officer, Senior Vice President, Secretary
  • Robert A. Seiser CPA, Vice President, Corporate Controller and Treasurer
  • J. Bradley Rivet, Vice President - Marketing
  • Albert W. Brzeczko Ph.D., Vice President -Technical Affairs
  • James F. Emigh, Vice President - Corporate Development
  • George K. Ross, Independent Director
  • William G. Skelly, Independent Director
  • Immanuel Thangaraj, Independent Director
  • Bruce F. Wesson, Independent Director

Who owns Acura Pharmaceuticals stock?

Acura Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include SCHUTTE JOHN (47.50%). View Institutional Ownership Trends for Acura Pharmaceuticals.

How do I buy Acura Pharmaceuticals stock?

Shares of Acura Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acura Pharmaceuticals' stock price today?

One share of Acura Pharmaceuticals stock can currently be purchased for approximately $0.41.

MarketBeat Community Rating for Acura Pharmaceuticals (NASDAQ ACUR)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  99 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  175
MarketBeat's community ratings are surveys of what our community members think about Acura Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Acura Pharmaceuticals (NASDAQ:ACUR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Acura Pharmaceuticals (NASDAQ:ACUR)
Price Target History for Acura Pharmaceuticals (NASDAQ:ACUR)
Analysts' Ratings History for Acura Pharmaceuticals (NASDAQ:ACUR)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/21/2016FBR & CoReiterated RatingOutperform$10.00N/AView Rating Details
10/18/2016Roth CapitalSet Price TargetBuy$6.00N/AView Rating Details
(Data available from 10/22/2015 forward)


Earnings History for Acura Pharmaceuticals (NASDAQ:ACUR)
Earnings by Quarter for Acura Pharmaceuticals (NASDAQ:ACUR)
Earnings History by Quarter for Acura Pharmaceuticals (NASDAQ ACUR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2017Q2 2017($0.11)($0.18)$0.09 millionViewN/AView Earnings Details
5/12/2017Q1 2017($0.11)$0.03$0.34 million$2.72 millionViewN/AView Earnings Details
11/14/2016Q3($0.27)($0.19)$0.23 million$0.22 millionViewN/AView Earnings Details
8/8/2016Q2($0.28)($0.28)$0.19 million$0.26 millionViewN/AView Earnings Details
5/2/2016Q116($0.26)($0.28)$0.15 million$0.22 millionViewN/AView Earnings Details
2/29/2016Q315($0.03)($0.08)$2.70 million$2.68 millionViewListenView Earnings Details
8/3/2015Q215($0.02)($0.05)$2.90 million$0.34 millionViewN/AView Earnings Details
5/4/2015Q115$0.07$0.03$7.60 million$5.40 millionViewN/AView Earnings Details
3/2/2015Q414($0.09)($0.06)$0.05 million$0.53 millionViewN/AView Earnings Details
11/3/2014Q3 2014($0.08)($0.06)$0.05 million$0.15 millionViewN/AView Earnings Details
3/3/2014Q4 13($0.06)($0.29)ViewN/AView Earnings Details
8/1/2013Q2 2013($0.07)ViewN/AView Earnings Details
3/4/2013Q4 2012($0.86)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Acura Pharmaceuticals (NASDAQ:ACUR)
Current Year EPS Consensus Estimate: $-0.4600 EPS
Next Year EPS Consensus Estimate: $0.3700 EPS


Dividend History for Acura Pharmaceuticals (NASDAQ:ACUR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Acura Pharmaceuticals (NASDAQ:ACUR)
Insider Ownership Percentage: 7.40%
Institutional Ownership Percentage: 31.23%
Insider Trades by Quarter for Acura Pharmaceuticals (NASDAQ:ACUR)
Institutional Ownership by Quarter for Acura Pharmaceuticals (NASDAQ:ACUR)
Insider Trades by Quarter for Acura Pharmaceuticals (NASDAQ:ACUR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/29/2017Albert W BrzeczkoVPBuy10,800$0.47$5,076.00View SEC Filing  
6/17/2015Claudius LlcMajor ShareholderSell104,823$1.08$113,208.84View SEC Filing  
1/12/2015Claudius LlcMajor ShareholderSell171,000$0.62$106,020.00View SEC Filing  
5/22/2014William G SkellyDirectorSell4,600$1.23$5,658.00View SEC Filing  
5/20/2014William G SkellyDirectorSell5,000$1.21$6,050.00View SEC Filing  
5/19/2014Albert W BrzeczkoVPBuy2,000$1.20$2,400.00View SEC Filing  
5/16/2014Bruce F WessonDirectorBuy80,000$1.13$90,400.00View SEC Filing  
5/16/2014James F EmighVPBuy15,000$1.21$18,150.00View SEC Filing  
5/16/2014Peter A ClemensCFOBuy3,000$1.21$3,630.00View SEC Filing  
5/14/2014William G SkellyDirectorSell2,900$1.21$3,509.00View SEC Filing  
5/12/2014William G SkellyDirectorSell5,000$1.25$6,250.00View SEC Filing  
5/8/2014William G SkellyDirectorSell2,500$1.30$3,250.00View SEC Filing  
3/3/2014Claudius LlcMajor ShareholderSell2,500$2.00$5,000.00View SEC Filing  
2/28/2014Claudius LlcMajor ShareholderSell351,260$2.02$709,545.20View SEC Filing  
2/24/2014Claudius LlcMajor ShareholderSell44,019$1.97$86,717.43View SEC Filing  
11/25/2013Albert W BrzeczkoVPBuy1,215$1.70$2,065.50View SEC Filing  
10/10/2013Claudius LlcMajor ShareholderSell4,200$2.05$8,610.00View SEC Filing  
8/27/2013William G SkellyDirectorSell2,000$1.55$3,100.00View SEC Filing  
7/15/2013Care Capital Ii LlcMajor ShareholderSell31,610$2.04$64,484.40View SEC Filing  
7/3/2013Care Capital Ii LlcMajor ShareholderSell14,200$2.00$28,400.00View SEC Filing  
7/2/2013Claudius LlcMajor ShareholderSell200,000$2.15$430,000.00View SEC Filing  
6/27/2013Care Capital Ii LlcMajor ShareholderSell76,281$2.01$153,324.81View SEC Filing  
6/24/2013Care Capital Ii LlcMajor ShareholderSell83,000$2.03$168,490.00View SEC Filing  
6/19/2013Care Capital Ii LlcMajor ShareholderSell114,000$2.12$241,680.00View SEC Filing  
6/17/2013Claudius LlcMajor ShareholderSell20,446$2.15$43,958.90View SEC Filing  
6/14/2013Care Capital Ii LlcMajor ShareholderSell90,000$2.16$194,400.00View SEC Filing  
6/11/2013Care Capital Ii LlcMajor ShareholderSell102,000$2.19$223,380.00View SEC Filing  
6/10/2013Claudius LlcMajor ShareholderSell21,496$2.20$47,291.20View SEC Filing  
6/6/2013Claudius LlcMajor ShareholderSell39,453$2.19$86,402.07View SEC Filing  
6/3/2013Care Capital Ii LlcMajor ShareholderSell148,000$2.24$331,520.00View SEC Filing  
5/31/2013Claudius LlcMajor ShareholderSell31,559$2.25$71,007.75View SEC Filing  
5/29/2013Care Capital Ii LlcMajor ShareholderSell108,701$2.33$253,273.33View SEC Filing  
5/28/2013William G SkellyDirectorSell2,000$2.40$4,800.00View SEC Filing  
5/23/2013Care Capital Ii LlcMajor ShareholderSell252,000$2.31$582,120.00View SEC Filing  
5/22/2013William G SkellyDirectorSell4,000$2.33$9,320.00View SEC Filing  
5/21/2013Claudius LlcMajor ShareholderSell47,410$2.30$109,043.00View SEC Filing  
5/20/2013Care Capital Ii LlcMajor ShareholderSell510,000$2.36$1,203,600.00View SEC Filing  
5/16/2013Care Capital Ii LlcMajor ShareholderSell662,000$2.38$1,575,560.00View SEC Filing  
5/16/2013William G SkellyDirectorSell3,000$2.25$6,750.00View SEC Filing  
5/15/2013Claudius LlcMajor ShareholderSell183,434$2.33$427,401.22View SEC Filing  
5/13/2013Care Capital Ii LlcMajor ShareholderSell259,000$2.19$567,210.00View SEC Filing  
5/9/2013William G SkellyDirectorSell3,000$2.20$6,600.00View SEC Filing  
4/11/2013Claudius LlcMajor ShareholderSell121,454$2.23$270,842.42View SEC Filing  
3/26/2013Care Capital Ii LlcMajor ShareholderSell39,554$2.17$85,832.18View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Acura Pharmaceuticals (NASDAQ:ACUR)
Latest Headlines for Acura Pharmaceuticals (NASDAQ:ACUR)
Loading headlines, please wait.



Acura Pharmaceuticals (ACUR) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.